Join
Live feed
·
PRReleasevia Quantisnow
Structure Therapeutics Inc. logo

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

ByQuantisnow·Wall Street's wire, on your screen.
GPCR· Structure Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GPCR (Structure Therapeutics Inc.) and more on Quantisnow.